On a scale of 0 to 100, United Therapeutic holds a
performance score of 14. The entity has a beta of 1.2634, which indicates a somewhat significant risk relative to the market. Let's try to break down what United's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, United Therapeutic will likely underperform. Although it is vital to follow
United Therapeutic current price movements, it is good to be conservative about what you can do with the information regarding equity historical returns. The philosophy towards measuring
future performance of any stock is to evaluate the business as a whole together with its past performance, including all
available fundamental and
technical indicators. By inspecting
United Therapeutic technical indicators, you can presently evaluate if the expected return of 0.42% will be sustainable into the future. Please operates United Therapeutic
coefficient of variation,
maximum drawdown, as well as the
relationship between the Maximum Drawdown and
skewness to make a quick decision on whether United Therapeutic existing
price patterns will revert.
The successful prediction of United Therapeutics
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as United Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of United Therapeutics based on United Therapeutics hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to United Therapeutics's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to United Therapeutics's related companies.
Use Technical Analysis to project United expected Price
United Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of United Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of United Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...What is the case for United Therapeutics Investors
The company reported the previous year's revenue of 1.41
B. Net Income was 468.6
M with profit before overhead, payroll, taxes, and interest of 1.33
B.
| 2018 | 2020 | 2021 (projected) |
PPandE Turnover | 2.61 | 1.81 | 2.04 | Calculated Tax Rate | 22.36 | 20.13 | 24.52 |
Cost of Revenue Breakdown
United Therapeutic Cost of Revenue yearly trend continues to be relatively stable with very little volatility. Cost of Revenue is likely to drop to about 56
M. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. United Therapeutic Cost of Revenue is relatively stable at the moment as compared to the past year. United Therapeutic reported last year Cost of Revenue of 65.43 Million
| 2011 | 88.9 Million |
| 2012 | 119.3 Million |
| 2013 | 131.13 Million |
| 2014 | 125.9 Million |
| 2015 | 69 Million |
| 2016 | 72.7 Million |
| 2020 | 65.43 Million |
| 2021 | 56.04 Million |
How will United retail investors react to the next fall?
Coefficient of variation is down to 614.91. It may connote a possible volatility fall. United Therapeutic has relatively low volatility with skewness of 0.12 and kurtosis of 0.41. However, we advise all investors to independently investigate United Therapeutic to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure United Therapeutic's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact United Therapeutic's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Takeaway on United Therapeutic Investment
While some firms in the biotechnology industry are either recovering or due for a correction, United Therapeutic may not be performing as strong as the other in terms of long-term growth potentials. The bottom line, as of the 24th of February 2021, our research shows that United Therapeutic is a rather very steady investment opportunity with a
low chance of financial distress in the next two years. From a slightly different view, the entity currently appears to be
undervalued. Our ongoing 30 days buy-or-sell advice on the enterprise is
Strong Buy.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of United Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com